bpc-157 legal status us 2025 Heal or Harm: Body Protective Compound-157 in the Gray Zone FDA Compliance for Peptide Therapy

BPC-157 promotes angiogenesis, which raises questions about use in individuals with active cancers where blood vessel growth could support tumor progression

Eligible residents may exercise applicable rights using the contact method above

For cognitive and mood applications in healthy individuals, the standard protocol uses a 0.1% solution, with one to two drops administered intranasally twice daily

Combining BPC-157 with Other Approaches BPC-157 works through distinct mechanisms from conventional GERD medications, creating potential for complementary combination approaches

Information provided is for educational and scientific discussion purposes only.

On 23 July 2026 an FDA advisory committee voted 8 to 6, with one abstention, to recommend that BPC-157 be added to a list of substances compounding pharmacies are permitted to use